Ramón García‐Sánz

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

Juan Flores‐Montero, Luzalba Sanoja-Flores, Bruno Paiva et al. · Leukemia · 2017 · 657 citations · Full text

Medicine, Hematology, Oncology +15

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

Ernesto Pérez Persona, María‐Belén Vídriales, Gema Mateo et al. · Blood · 2007 · 575 citations · Full text

Medicine, Hematology, Pathology +17

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations · Full text

Medicine, Hematology, Pharmacology +17

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S. Tam, Stephen Opat, Shirley D’Sa et al. · Blood · 2020 · 448 citations · Full text

Medicine, Hematology, Pharmacology +4